• Vijay Agarwal, Michael J Lind, and Lynn Cawkwell.
• Cancer Biology Proteomics Group, Postgraduate Medical Institute of the University of Hull and Hull York Medical School, Hull, UK.
• Cancer Treat. Rev. 2011 Nov 1;37(7):533-42.

AbstractThe median survival for patients with malignant pleural mesothelioma remains extremely poor and there is a need for the development of more effective treatment modalities. The epidermal growth factor receptor is frequently over-expressed in malignant pleural mesothelioma samples and therefore may be a potential therapeutic target. Targeted EGFR therapy has been successful in non-small cell lung cancer using small molecule tyrosine kinase inhibitors and in colorectal cancer using monoclonal anti-EGFR antibodies. However, phase II clinical trials based on EGFR tyrosine kinase inhibitor therapy have so far not shown promise in mesothelioma. This review includes a background to targeted EGFR treatment strategies, explores putative therapy resistance mechanisms, including the role of predictive biomarkers, and describes the current status of targeted EGFR therapeutic strategies for mesothelioma patients.Copyright © 2010 Elsevier Ltd. All rights reserved.

14 keywords...

hide…